EC Pharmacology and Toxicology

Mini Review Volume 14 Issue 2 - 2026

The Emerging Role of miRNA in Pancreatic Adenocarcinoma: Mechanisms, Diagnostics, and Therapeutic Potential

S Jeyaparvathi1, R Caroline Seba2, P Sumathi3 and M Baranitharan1,3*

1Department of Zoology, St. Joseph University, Chumoukedima, Nagaland, India

2Department of Biotechnology, Dr.M.G.R. Educational and Research Institute, Maduravoyal, Chennai, India

3Department of Chemistry, Gobi Arts and Science College (Autonomous), Gobichettipalayam, Erode, India

*Corresponding Author: M Baranitharan, Department of Zoology, St. Joseph University, Chumoukedima, Nagaland and Department of Chemistry, Gobi Arts and Science College (Autonomous), Gobichettipalayam, Erode, India.
Received: November 26, 2025; Published: February 04, 2026



miRNAs were first identified in Caenorhabditis elegans in the early 1990s, but have since been reported in a wide variety of organisms ranging from single-cell algae to humans, suggesting that miRNA-mediated biological function is an ancient and critical cellular regulatory system and microRNAs (miRNAs) are small non-coding RNAs that are crucial regulators of carcinogenesis. The deregulation of miRNAs in prostate cancer was investigated. miRNA microarray profiling was performed in fresh frozen prostate cancer and matched normal adjacent tissues. Differentially expressed miRNAs were subsequently validated by real-time quantitative PCR (RT-qPCR). Fifteen miRNAs differentially regulated in prostate cancer in comparison with normal tissue. Expression of 5 miRNAs was correlated with the pathological stage and the Gleason score. MicroRNAs (miRNAs) are small noncoding RNAs (18-25 nucleotides) that regulate gene expression post-transcriptionally. MicroRNAs (miRNAs) are small non-coding, endogenous, single-stranded RNAs. MiRNAs have been implicated in different areas such as the immune response, neural development, DNA repair, apoptosis, oxidative stress response and cancer.

 Keywords: miRNA; Pancreatic Carcinoma; miRNA Signatures; Cancer

  1. Hanahan D and Weinberg RA. “Hallmarks of cancer: the next generation”. Cell 5 (2011): 646-674.
  2. Jafari S., et al. “The roles of lncRNAs and miRNAs in pancreatic cancer: a focus on cancer development and progression and their roles as potential biomarkers”. Frontiers in Oncology 14 (2024): 1355064.
  3. Russo SK., et al. “Pancreas-enriched miRNA refines endocrine cell differentiation”. Development16 (2012): 3021-3031.
  4. Ogunwobi OO and Segura MF. “PVT1 in cancer”. Frontiers in Oncology 10 (2020): 588786.
  5. Sattari M., et al. “The expression levels of MicroRNA-146a, RANKL and OPG after non-surgical periodontal treatment”. BMC Oral Health 21 (2021): 523.
  6. Calin GA., et al. “A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia”. New England Journal of Medicine 17 (2005): 1793-1801.
  7. Garzon R., et al. “MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia”. Blood6 (2008): 3183-3189.
  8. Mi S., et al. “MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia”. Proceedings of the National Academy of Sciences of the United States of America 50 (2007): 19971-19976.
  9. Allegra A., et al. “Circulating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer”. International Journal of Oncology 6 (2012): 1897-1912.
  10. Bandyopadhyay S., et al. “Development of the human cancer microRNA Network”. Silence1 (2010): 6.
  11. Li H-N., et al. “Contributions of HOTAIR polymorphisms to the susceptibility of cancer”. International Journal of Clinical Oncology 26 (2021): 1022-1038.
  12. Zhang Y., et al. “Profiling of 95 MicroRNAs in pancreatic cancer cell lines and surgical specimens by real time PCR analysis”. World Journal of Surgery 4 (2009): 698-709.
  13. Ellie TY Mok., et al. “miRNAs in pancreatic cancer progression and metastasis”. Clinical and Experimental Metastasis 41 (2024): 163-186.
  14. Bauer AS., et al. “Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue”. Plos One4 (2012): e34151.
  15. Bloomston M., et al. “MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis”. Journal of the American Medical Association 17 (2007): 1901-1908.
  16. Cai B., et al. “miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2”. Oncology Reports 5 (2013): 1769-1776.
  17. Ilic I and Ilic M. “International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: a joinpoint regression analysis”. World Journal of Gastroenterology 32 (2022): 4698-4715.
  18. Luzi E., et al. “MicroRNAs and pancreatic-endocrine system”. Noncoding RNAs in Endocrinology 1 (2013): 9-15.
  19. Sinkam NSP., et al. “MicroRNAs in cancer: personalizing diagnosis and therapy”. Annals of the New York Academy of Sciences 1210 (2010): 25-33.
  20. Jones GS., et al. “miRBase: microRNA sequences, targets and gene nomenclature”. Nucleic Acids Research 34 (2006): D140-D144.
  21. Chi B., et al. “Increased expression of miR-194-5p through the circPVRL3/miR-194-5p/SOCS2 axis promotes proliferation and metastasis in pancreatic ductal adenocarcinoma by activating the PI3K/AKT signaling pathway”. Cancer Cell International 1 (2022): 415.
  22. Liu J., et al. “Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer”. International Journal of Cancer 3 (2012): 683-691.
  23. Weimer EAC. “The role of microRNAs in cancer: no small matter”. European Journal of Cancer 10 (2007): 1529-1544.
  24. Linda SL., et al. “Investigating MicroRNA expression profiles in pancreatic cystic neoplasms”. Clinical and Translational Gastroenterology 5 (2014): e47.
  25. Schultz NA., et al. “MicroRNA biomarkers in whole blood for detection of pancreatic cancer”. Journal of the American Medical Association4 (2014): 392-404.
  26. Sadakari Y., et al. “MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma”. Journal of the Pancreas 11.6 (2010): 587-592.
  27. Panarelli NC and Yantiss RK. “MicroRNA expression in selected carcinomas of the gastrointestinal tract”. Pathology Research International (2011): 124608.
  28. Ma MZ., et al. “Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance”. Journal of Experimental and Clinical Cancer Research 1 (2013): 71.
  29. Schwarzbach SAE., et al. “Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma”. Expert Review of Molecular Diagnostics 3 (2011): 249-257.
  30. Marcucci G., et al. “MicroRNA expression in cytogenetically normal acute myeloid leukemia”. New England Journal of Medicine 18 (2008).
  31. Xu C and Qi X. “MiR-10b inhibits migration and invasion of pancreatic ductal adenocarcinoma via regulating E2F7”. Journal of Clinical Laboratory Analysis 10 (2020): 23442.
  32. Oliver AK., et al. “A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells”. Cancer Biology and Therapy 21 (2009): 2013-2024.
  33. Wang L., et al. “microRNA-26a represses pancreatic cancer cell malignant behaviors by targeting E2F7”. Discover Oncology 1 (2021): 55.

M Baranitharan., et al. “The Emerging Role of miRNA in Pancreatic Adenocarcinoma: Mechanisms, Diagnostics, and Therapeutic Potential”. EC Pharmacology and Toxicology  14.2 (2026): 01-05.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net